Physicians' Academy for Cardiovascular Education

Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure

Meeting report with video, highlights and slides of PACE-CME symposium held at ESC 2017 in Barcelona, more items to follow...

Meeting Impression | Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure

August 28, 2017 - ESC
August 28, 2017 - ESC

In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, the role of diabetes treatment in the management of heart failure, as well as novel interventions targeted to improve CV outcomes were discussed.

Summary | Heart failure & Diabetes: Time for a more unified approach

August 28, 2017 - Prof. Stefan Anker (Berlin, Germany)
August 28, 2017 - Prof. Stefan Anker (Berlin, Germany)

Lessons learned from the EMPA-REG OUTCOME trial: prof Anker suggested that empagliflozin may prevent the development of HF. However, he emphasized that new trials are needed to test the effect of SGLT2 inhibitors in the treatment of HF in diabetes patients.

Summary | Management of CV Risk & T2DM: Implications of novel outcome trials

August 28, 2017 - Prof. John Deanfield (London, UK)
August 28, 2017 - Prof. John Deanfield (London, UK)

A summary of the beneficial effects of the SGLT2 inhibitor empagliflozin and GLP-1 receptor agonist liraglutide on CV outcome in patients with diabetes and CVD was given by prof. Deanfield. He raised the point that this is a new era for CVD management in diabetes patients and discussed current and future studies.

Summary | SGLT2 inhibition in cardiology: What a cardiologist needs to know

August 28, 2017 - Prof. Naveed Sattar (Oxford, UK)
August 28, 2017 - Prof. Naveed Sattar (Oxford, UK)

Prof. Sattar described how the EMPA-REG OUTCOME trial introduced a new class of drugs, the SGLT2 inhibitor empagliflozin, with great CV benefits in patients with diabetes and CVD. Furthermore, the mechanism of action of empagliflozin by improving kidney function and reduction of flow and volume was discussed.

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME
PACE-CME symposium held at ESC 2017 - Heart failure & Diabetes: Time for a more unified approach

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME
SGLT2 inhibition in cardiology: What a cardiologist needs to know

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017